Phlebitis is a well-described adverse effect of intravenous (IV) administration of amiodarone, with reported incidence ranging from 11% to 85%” Dixon et al (2019).
Extract:
Phlebitis is a well-described adverse effect of intravenous (IV) administration of amiodarone, with reported incidence ranging from 11% to 85%. Risk factors for amiodarone-induced phlebitis (AIP) are many and include peripheral infusion, concentrations exceeding 2 mg/mL, higher dose of amiodarone administered via a single line, the absence of in-line filters, suboptimal aseptic technique during line insertion, absence of post-infusion line flushing, poor vein condition, older age, female sex, administration errors, and the concurrent administration of other medications known to cause phlebitis.
You may also be interested in…
[rp4wp]
[button link=”https://journals.sagepub.com/doi/pdf/10.1177/1129729819838123″ color=”default”]Full Text[/button]
[spacer height=”20px”]
Reference:
Dixon, H.A., Hort, A.L. and Wright, C.M. (2019) Amiodarone-induced phlebitis remains an issue in spite of measures to reduce its occurrence. The Journal of Vascular Access. April 8th. https://doi.org/10.1177/1129729819838123. [epub ahead of print].